Current Report Filing (8-k)
June 09 2020 - 01:29PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934
Date
of Report (Date of earliest event reported): June 9, 2020
THERAPEUTIC SOLUTONS INTERNATIONAL,
INC.
|
(Exact
Name of Registrant as Specified in its Charter)
|
Nevada
|
|
000-54554
|
|
45-1226465
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification Number)
|
4093 Oceanside Boulevard, Suite B
|
Oceanside, California 92056
|
(Address of Principal Executive Offices and Zip Code)
|
|
(760) 295-7208
|
(Issuer's telephone number)
|
|
Not
Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[
] Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[
] Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other Events.
On
May 8, 2020, Therapeutic Solutions International, Inc. released the
following headline in a press release “Therapeutic Solutions
International Initiates 500 Volunteer COVID-19 Prevention Clinical
Trial Using QuadraMune™”. The new clinical trial has been granted
ClinicalTrials.gov Identifier: NCT04421391 on Friday June
5th. On June 9, 2020 the Protocol Registration and
Results System (PRS) has posted our registration and is available
on the Federal Clinical Trial registry at this link
https://clinicaltrials.gov/ct2/show/NCT04421391
Item 9.01 Financial Statements and Exhibits.
Exhibit Index
(99)Press
release dated May 8, 2020, issued by Therapeutic Solutions
International, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date:
May 9, 2020
THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
By:
/s/ Timothy
Dixon
Timothy Dixon
Chief
Executive Officer
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Dec 2020 to Jan 2021
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Jan 2020 to Jan 2021